About this study
This study will be looking at whether a medicinal cannabinoid (CBD) product can improve sleep outcomes and general wellbeing in adults with moderate to severe insomnia. It will also examine the effect on cognition, mood and general wellbeing.
Participation will involve taking an oral cannabidiol (CBD) treatment or placebo nightly for a three-week period. Participants will also complete a daily sleep-monitoring diary and treatment log.
During the trial, participants will be asked to attend Swinburne University on five separate occasions:
- one screening session for a maximum of 1.5 hours
- four check-in and compliance sessions of 45 minutes each.
Participants may be eligible if aged 18 to 45 years and presenting with moderate to severe sleeping difficulties, such as difficulty falling or staying asleep, dissatisfaction with current sleep patterns, or sleep problems interfering with daily life. Additional criteria apply.